CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Coeptis Therapeutics Holdings Inc is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Coeptis Therapeutics Holdings Inc
105 Bradford Road, Suite 420
Phone: (724) 934-6467p:724 934-6467 WEXFORD, PA  15090  United States Ticker: COEPCOEP

Business Summary
Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company developing cell therapy platforms for cancer, autoimmune, and infectious diseases. Its product portfolio is highlighted by assets licensed from Deverra Therapeutics, including an allogeneic cellular immunotherapy platform and DVX201, a clinical-stage, unmodified natural killer cell therapy technology. It is developing a universal, multi-antigen CAR technology licensed from the University of Pittsburgh (SNAP-CAR), and the GEAR cell therapy and companion diagnostic platforms in collaboration with VyGen-Bio and medical researchers at the Karolinska Institute. Its NexGenAI Affiliates Network platform offers AI-powered marketing software and advanced robotic process automation capabilities. Its Coeptis Technologies division is focused on diversifying and enhancing its growth potential. Its subsidiaries include Coeptis Therapeutics, Inc., Coeptis Pharmaceuticals, Inc., GEAR Therapeutics, Inc. and SNAP Biosciences, Inc.

Scores and Ratings
FRISK®
Score
Z''
Score
PAYCE®
Score
DBT
Index
Moody's
Rating
Fitch
Rating
DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement
Last
Audit

News
SEC
Filings
Bankruptcy
Filings
Suit &
Judgment
Filings
Tax
Lien
Filings
9/30/202412/31/2023YesYes---

Subsidiaries
Business Name Address City State/Province Country
Coeptis Pharmaceuticals, Inc. 105 Bradford Rd Wexford PA United States
Coeptis Therapeutics, Inc. 105 Bradford Rd, Suite 420 WEXFORD PA United States

Business Names
Business Name
BHSE
BHSEU
COEP
12 additional Business Names available in full report.

General Information
Number of Employees: 5 (As of 12/31/2023)
Outstanding Shares: 2,848,068 (As of 1/17/2025)
Shareholders: 112
Stock Exchange: NASD
Federal Tax Id: 981465952
Fax Number: (302) 636-5454


Copyright © 2025 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Friday, January 31, 2025